Enhanced Immune Reconstitution and Reduced GvHD Risk with T-allo10 Infusion Post A βdepleted-HSCT in Pediatric and Young Adult Patients with Hematologic Malignancies

Allogeneic hematopoietic stem cell transplantation (HSCT) has been historically hindered by the scarcity of HLA-matched donors. TCR αβ+ T-cell and CD19+ B-cell-depleted (αβdepleted) HSCT has expanded the utilization of HLA-mismatched donors by reducing the incidence of severe graft-versus-host disease (GvHD). However, αβdepleted-HSCT still presents challenges such as viral reactivations (∼50%) and leukemic relapse (25-30 %) due to suboptimal immune reconstitution (IR).To address these hurdles, we combined αβdepleted-HSCT with a newly developed T-cell immunotherapy known as T-allo10.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Alice Bertaina, Rosa Bacchetta, David C. Shyr, Gopin Saini, Jennifer Lee, Karen Kristovich, Rajni Agarwal-Hashmi, Dr. Orly R. Klein, Kathryn Melsop, Keri Tate, Giulia Barbarito, Linda Oppizzi, Pauline Chen, Matthew H. Porteus, Alma-Martina Cepika, Maria G Tags: 16 Source Type: research